Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

PMID:
23121378
[PubMed - indexed for MEDLINE]
Free Article
2.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group.

Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Erratum in: Am J Kidney Dis. 2012 Feb;59(2):318.

PMID:
21872376
[PubMed - indexed for MEDLINE]
3.

[Diagnosis of diabetes mellitus: limited use for portable blood-glucose measuring devices].

Houweling ST, Kleefstra N, van Ballegooie E, Miedema K, Rischen R, Heeg JE.

Ned Tijdschr Geneeskd. 2005 Mar 26;149(13):694-7. Review. Dutch.

PMID:
15819134
[PubMed - indexed for MEDLINE]
4.

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E; Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group.

Diabetes Care. 2004 May;27(5):1081-7.

PMID:
15111525
[PubMed - indexed for MEDLINE]
5.

ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.

van der Kleij FG, Navis GJ, Gansevoort RT, Heeg JE, Scheffer H, de Zeeuw D, de Jong PE.

Nephrol Dial Transplant. 1997;12 Suppl 2:42-6.

PMID:
9269699
[PubMed - indexed for MEDLINE]
6.

Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.

Gansevoort RT, Heeg JE, Dikkeschei FD, de Zeeuw D, de Jong PE, Dullaart RP.

Nephrol Dial Transplant. 1994;9(3):244-50.

PMID:
8052429
[PubMed - indexed for MEDLINE]
7.

The antiproteinuric effect of ACE inhibition in renal disease.

Heeg JE.

Pharm World Sci. 1993 Oct 15;15(5):230-2. Review. No abstract available.

PMID:
8257961
[PubMed - indexed for MEDLINE]
8.

The antiproteinuric effect of antihypertensive agents in diabetic nephropathy.

Gansevoort RT, Apperloo AJ, Heeg JE, de Jong PE, de Zeeuw D.

Arch Intern Med. 1992 Oct;152(10):2137-9. No abstract available.

PMID:
1417388
[PubMed - indexed for MEDLINE]
9.

The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.

de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D.

J Cardiovasc Pharmacol. 1992;19 Suppl 6:S28-32. Review.

PMID:
1382162
[PubMed - indexed for MEDLINE]
10.

Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy.

Gansevoort RT, Heeg JE, Vriesendorp R, de Zeeuw D, de Jong PE.

Nephrol Dial Transplant. 1992;7 Suppl 1:91-6.

PMID:
1337189
[PubMed - indexed for MEDLINE]
11.

Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.

Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D.

Kidney Int. 1991 Oct;40(4):734-41.

PMID:
1660550
[PubMed - indexed for MEDLINE]
12.
13.

Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.

de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D.

Am J Kidney Dis. 1991 May;17(5 Suppl 1):85-8. Review. No abstract available.

PMID:
2024682
[PubMed - indexed for MEDLINE]
14.

Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril.

Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D.

Am J Nephrol. 1990;10 Suppl 1:94-7.

PMID:
2175149
[PubMed - indexed for MEDLINE]
15.

Lisinopril in hypertensive patients with renal function impairment.

de Jong PE, Apperloo AJ, Heeg JE, de Zeeuw D.

Nephron. 1990;55 Suppl 1:43-8.

PMID:
2161083
[PubMed - indexed for MEDLINE]
16.

Mechanism of the antiproteinuric effect of angiotensin-converting enzyme inhibition.

de Zeeuw D, Heeg JE, Stelwagen T, de Jong RJ, de Jong PE.

Contrib Nephrol. 1990;83:160-5. No abstract available.

PMID:
1966072
[PubMed - indexed for MEDLINE]
17.

Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D.

Kidney Int. 1989 Aug;36(2):272-9.

PMID:
2550696
[PubMed - indexed for MEDLINE]
18.

Lisinopril and renal failure.

Heeg JE, de Jong PE, de Zeeuw D.

Lancet. 1989 Apr 15;1(8642):846. No abstract available.

PMID:
2564931
[PubMed - indexed for MEDLINE]
19.

Antiproteinuric effect of ACE inhibitors.

Heeg JE, de Zeeuw D, de Jong PE.

Lancet. 1988 Nov 26;2(8622):1251-2. No abstract available.

PMID:
2903981
[PubMed - indexed for MEDLINE]
20.

Churg-Strauss syndrome with severe polyradiculoneuropathy and unilateral nerve deafness.

Heeg JE, van Rijswijk MH, Hazenberg BP, van Leeuwen MA.

Neth J Med. 1988 Apr;32(3-4):185-93. No abstract available.

PMID:
3362270
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk